Ceftriaxone does not reach the brain
Under normal circumstances, Ceftriaxone (brand name Rocephin) does not enter the central nervous system and therefore is useless against ALS or Lyme disease, especially in the doses typically used.
Trials to treat ALS with Ceftriaxone are therefore doomed to fail, because Ceftriaxone does not pass the blood-brain barrier and thus does not reach a sufficient concentration in the central nervous system. The Chinese know this, why don't we? None of the antibiotics in the class of Cephalosporins enter the brain. Therefore, all these antibiotics are useless without using a method to let them pass the blood-brain barrier.
We can adopt a conspiratorial approach and say this was deliberate, but a simpler explanation exists: The problem with most medical specialists is that they are not scientists like engineers or mathematicians. They are more comparable with bureaucrats or lawyers. They learn some facts, blindly accept them but do not understand the reasons behind them. Doctors think that because Ceftriaxone cures brain infections such as Meningitis, that it passes the blood-brain barrier. However, they do not understand that Ceftriaxone only passes the bbb because the capillary vessels are inflamed. Without such inflammation, there is no bbb penetration, since Ceftriaxone's molecule is not lipid-soluble and < 500 Daltons.
Lyme neuroborreliosis often does not result in Meningitis. Meningitis is the inflamation of the capillary bloodvessels that form the blood-brain barrier. Meningitis degrades the structural integrity of these vessels, and an increased penetrability for larger molecules is the result. There often only occurs Lyme Meningitis in the acute untreated stage and as soon as antibiotics reach that area, the Meningitis subsides and Cef will not penetrate anymore, leaving the remaining bacteria unexposed. Bb s.l. is microaerophillic so it moves out of the Oxygen-rich parenchyma and nestles deeper in the brain, such as inside neurons. It has a great tropism for Myelin as well.
The below study shows that Ceftriaxone does not penetrate the bbb, except in the presence of Meningitis:
Zhonghua Nei Ke Za Zhi. 1989 Jun;28(6):340-2, 381.
[The penetration of cephalosporins across the blood-brain barrier and its clinical significance].
[Article in Chinese]
Zhang YY, Wu PJ, Zhang Q.
"The penetration of Cefuroxime (CXM), Ceftazidime (CTZ), Cefotaxime (CTX), Ceftizoxime (CZX), and Ceftriaxone (CTRX) across the blood-brain barrier was studied in 119 patients with or without meningitis after an intravenous injection of 2 grams. Cephalosporins were undetectable or their concentrations very low in the cerebrospinal fluid (CSF), when there was no inflammation in the meninges. On the contrary, the mean CSF concentrations of cephalosporins were 2.21-5.36 micrograms/ml and the CSF/serum ratios 3.73-31.80% in acute stage of purulent meningitis."